药康生物: 2-4 milyon yuanlık hisse senedi geri alımı planlanıyor

robot
Abstract generation in progress

Gate.io data on November 7th, Yaoke Bio announced that the company plans to repurchase some of the company's already produced RMB ordinary shares through centralized bidding. The specific repurchase plan is as follows: the amount of repurchased shares is not less than RMB 22 million and not more than RMB 40 million; the source of funds for repurchasing shares is the company's own funds and special loan funds for stock repurchase; the repurchase price of shares does not exceed RMB 18 per share; the method of repurchasing shares is through centralized bidding; the repurchase period is within 12 months from the date when the company's board of directors approves the share repurchase plan. The company's directors, supervisors, senior management, controlling shareholders, and actual controllers have no definite plan to reduce their holdings in the next 3 months or the next 6 months.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)